去纤苷主要治疗哪些疾病？疗效如何

Defibrinoside is a multifunctional adenosine receptor agonist that enhances the enzymatic activity of plasmin that hydrolyzes fibrin clots. Studies evaluating the pharmacological effects of defibrotide on endothelial cells (ECs) have been primarily conducted in human microvascular endothelial cell lines. What diseases are mainly treated? How effective is it?

Indications for defibrination

Defibrotide is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), and renal or pulmonary dysfunction after hematopoietic stem cell transplantation (HSCT).

The therapeutic effect of defibrotide

A European research group reported the efficacy of defibrotide in 40 patients with hepatic veno-occlusive disease, 28 of whom were patients with severe hepatic veno-occlusive disease or multiple organ failure. The dosage of Defibrotide is 10~40 mg/kg/d, and the median application time is 18 days. The median time to start medication was +14 (-2 + 53) days after transplantation. The results showed that 55% of patients had complete remission and 43% of patients survived +100 days.

In clinical trials, heparin is usually used to prevent diseases such as hepatic veno-occlusive disease, which also greatly increases the patient's risk of bleeding. However, defibrotide (Defibrotide) alone or in combination with heparin has a low incidence of side effects, good safety, and has achieved good results in preventing hepatic veno-occlusive disease (VOD). Defibrotide is also currently recognized as the most promising drug for the treatment of hepatic veno-occlusive disease (VOD).

The above is an introduction to the indications and treatment effects of Defibrotide. If patients want to know more drug information about Defibrotide (such as drug prices, purchasing channels, etc.), they can consult the Medical Companion Travel Service at any time.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: